DEFINIUM THERAPEUTICS INC
DFTXNASDAQ🏆 #1240 by market capEarnings Nov 5US Equity
$38.68▲ $0.58 (+1.51%)
Latest quoteTrack DFTX
Get earnings, price moves & breaking news on Telegram
24h▲ 1.5%
7d▲ 7.4%
14d▲ 12.9%
30d▲ 1.3%
ytd▲ 188.7%
1y▲ 199.1%
🏦Market Cap
$5.20B
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $38.02 – $39.14
- 52-Week Range
- $10.47 – $49.70
- Volume (shares)
- 33,574
- Avg Volume (shares)
- —
- Shares Outstanding
- 134.4M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-3.43
- Dividend Yield
- —
- Dilution (1yr)
- +6.4%
DEFINIUM THERAPEUTICS INC
DFTXFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$166M▲ +60.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$132M▲ +66.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
89.3M▲ +6.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$258M▲ +$6M YoY
StockOtter · stockotter.spaceAbout DEFINIUM THERAPEUTICS INC
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
24 analysts
Strong Buy9
Buy14
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.